KALA BIO Inc Surges After $6 Million Investment Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 04 Dec 25
Source: 144
KALA BIO Inc shares rose by 16.76% in pre-market trading, breaking above the 5-day SMA. This movement follows the announcement of a $6 million securities purchase agreement with investor David E. Lazar.
The agreement will provide essential funding for KALA's ongoing research and aims to enhance its competitive position in treating eye diseases. Additionally, David E. Lazar has been appointed as the new CEO, bringing expertise in capital restructuring to the company.
Despite challenges faced in clinical trials, KALA's strategic planning and new leadership may create opportunities for growth and shareholder value in the future.
Analyst Views on KALA
About KALA
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
